NASDAQ:KLTO - Nasdaq - US49876K1034 - Common Stock - Currency: USD
NASDAQ:KLTO (5/23/2025, 12:49:48 PM)
0.1848
0 (-2.22%)
The current stock price of KLTO is 0.1848 USD. In the past month the price increased by 18.87%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 17.85 | 324.20B | ||
AMGN | AMGEN INC | 13.03 | 145.41B | ||
GILD | GILEAD SCIENCES INC | 13.8 | 133.00B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 111.76B | ||
REGN | REGENERON PHARMACEUTICALS | 13.27 | 63.47B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 37.26B | ||
ARGX | ARGENX SE - ADR | 99.28 | 35.58B | ||
ONC | BEIGENE LTD-ADR | 6.01 | 26.07B | ||
BNTX | BIONTECH SE-ADR | N/A | 23.45B | ||
NTRA | NATERA INC | N/A | 20.74B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.09B | ||
BIIB | BIOGEN INC | 7.9 | 18.30B |
Klotho Neurosciences, Inc. engages in the provision of new therapies to treat neurodegenerative diseases. The company is headquartered in New York City, New York and currently employs 3 full-time employees. The company went IPO on 2022-04-29. The firm's licensed platforms, namely, a generic drug portfolio and a biosimilar biologics platform uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Its primary focus is the advancement of a sustainable portfolio of cell and gene therapy product candidates for age-associated neurologic diseases, both rare orphan diseases and diseases in larger patient populations. The firm's two lead gene therapy product candidates are KLTO-101 (AAV9-CMV-sKL) for the treatment or prevention of Alzheimer’s disease, and KLTO-202 (AAVmyo-Des-sKL) gene therapy product for the treatment and prevention of Lou Gehrig’s disease (amyotrophic lateral sclerosis).
KLOTHO NEUROSCIENCES INC
1115 Broadway, 12th Floor
New York City NEW YORK US
Employees: 3
Phone: 16469165315
The current stock price of KLTO is 0.1848 USD. The price decreased by -2.22% in the last trading session.
The exchange symbol of KLOTHO NEUROSCIENCES INC is KLTO and it is listed on the Nasdaq exchange.
KLTO stock is listed on the Nasdaq exchange.
KLOTHO NEUROSCIENCES INC (KLTO) has a market capitalization of 5.27M USD. This makes KLTO a Nano Cap stock.
KLOTHO NEUROSCIENCES INC (KLTO) currently has 3 employees.
KLOTHO NEUROSCIENCES INC (KLTO) has a support level at 0.18 and a resistance level at 0.2. Check the full technical report for a detailed analysis of KLTO support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
KLTO does not pay a dividend.
KLOTHO NEUROSCIENCES INC (KLTO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.32).
The outstanding short interest for KLOTHO NEUROSCIENCES INC (KLTO) is 0.23% of its float. Check the ownership tab for more information on the KLTO short interest.
ChartMill assigns a technical rating of 2 / 10 to KLTO.
Over the last trailing twelve months KLTO reported a non-GAAP Earnings per Share(EPS) of -0.32. The EPS decreased by -405.93% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -250.28% | ||
ROE | -518.88% | ||
Debt/Equity | 0.23 |